Abstract

CEPI is an innovative partnership between public, private, philanthropic and civil organisations founded in Davos in 2017 to develop vaccines to stop future epidemics. To date, CEPI has received multi-year funding from Norway, Germany, Japan, the Bill & Melinda Gates Foundation, and the Wellcome Trust. CEPI has also received single-year investments from the governments of Australia, Belgium, and Canada. It has reached $630 million of its $1 billion funding target. The European Commission has announced a contribution in kind of €250 million that will support relevant projects through EC mechanisms. Since its launch in January 2017, CEPI has announced two Calls for Proposals. The first was for candidate vaccines against MERS-CoV, Nipah and Lassa viruses. The second was for the development of platforms that can be used for rapid vaccine development against unknown pathogens. From the first call, CEPI has, so far, announced six partnership agreements and this means 4 lassa vaccine candidates, 3 MERS-CoV vaccine candidates and 1 Nipah vaccine candidate have been selected for development. Learn more at CEPI.net. Follow us at @CEPIvaccines.